Previous Next

ARCHIVE

№1' 2013

THERAPY

International Medical Journal, Vol. 19., Iss. 1, 2013, P. 39−43.

The influence of inhibitor of activator of plasminogen-1 on cardiometabolic markers in patients with combined arterial hypertension and obesity

Kharkiv National Medical University, Kharkiv, Ukraine

Abstract. Investigation of the role of apokines in arterial hypertension development is an important field of investigation. The authors analyzed the influence of various levels of plasminogen−1 activator inhibitor (PAI) on formation of clinical metabolic disorders in patients with arterial hypertension and obesity. The levels of lipids and carbohydrates were determined using biochemical techniques, adipokines concentration using immunoenzyme techniques. The study involved 82 patients with arterial hypertension associated with obesity, men (25.61%) and women (74.39%), mean age 59.03+−1.47. The patients were divided into tretiles by PAI level (low, medium, high). In patients with arterial hypertension associated with obesity, increased PAI activity was associated with abdominal obesity, increased arterial pressure, glycometabolic and lipid disorders with formation of adipikine dysfunction manifesting by increased activity of tumor necrosis factor− α and hypoadiponectinemia.

Key words: arterial hypertension, obesity, inhibitor of activator of plasminogen−1, carbohydrates, lipids, adipokines.